Literature DB >> 20005223

Acute glial activation by stab injuries does not lead to overt damage or motor neuron degeneration in the G93A mutant SOD1 rat model of amyotrophic lateral sclerosis.

Masatoshi Suzuki1, Sandra Klein, Elizabeth A Wetzel, Michael Meyer, Jacalyn McHugh, Craig Tork, Antonio Hayes, Clive N Svendsen.   

Abstract

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease where motor neurons within the brain and spinal cord are lost, leading to paralysis and death. Recently, a correlation between head trauma and the incidence of ALS has been reported. Furthermore, new invasive neurosurgical studies are being planned which involve inserting needles directly to the spinal cord. We therefore tested whether acute trauma to the spinal cord via a knife wound injury would lead to accelerated disease progression in rodent models of ALS (SOD1(G93A) rats). A longitudinal stab injury using a small knife was performed within the lumbar spinal cord region of presymptomatic SOD1(G93A) rats. Host glial activation was detected in the lumbar area surrounding a micro-knife lesion at 2 weeks after surgery in both wild type and SOD1(G93A) animals. However, there was no sign of motor neuron loss in the injured spinal cord of any animal and normal motor function was maintained in the ipsilateral limb. These results indicate that motor neurons in presymptomatic G93A animals are not affected by an invasive puncture wound injury involving reactive astrocytes. Furthermore, acute trauma alone does not accelerate disease onset or progression in this ALS model which is important for future strategies of gene and cell therapies directly targeting the spinal cord of ALS patients. Copyright 2009 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20005223      PMCID: PMC2839070          DOI: 10.1016/j.expneurol.2009.12.004

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  38 in total

Review 1.  Amyotrophic lateral sclerosis. unfolding the toxicity of the misfolded.

Authors:  J P Julien
Journal:  Cell       Date:  2001-02-23       Impact factor: 41.582

2.  Stem cell treatment in Amyotrophic Lateral Sclerosis.

Authors:  Letizia Mazzini; Katia Mareschi; Ivana Ferrero; Elena Vassallo; Giuseppe Oliveri; Nicola Nasuelli; Gaia Donata Oggioni; Lucia Testa; Franca Fagioli
Journal:  J Neurol Sci       Date:  2007-06-19       Impact factor: 3.181

Review 3.  Crosstalk between astrocytes and motor neurons: what is the message?

Authors:  L Van Den Bosch; W Robberecht
Journal:  Exp Neurol       Date:  2008-01-26       Impact factor: 5.330

Review 4.  Neuroinflammation in spinal cord injury: therapeutic targets for neuroprotection and regeneration.

Authors:  Jessica K Alexander; Phillip G Popovich
Journal:  Prog Brain Res       Date:  2009       Impact factor: 2.453

5.  Non-cell-autonomous effect of human SOD1 G37R astrocytes on motor neurons derived from human embryonic stem cells.

Authors:  Maria C N Marchetto; Alysson R Muotri; Yangling Mu; Alan M Smith; Gabriela G Cezar; Fred H Gage
Journal:  Cell Stem Cell       Date:  2008-12-04       Impact factor: 24.633

6.  Human embryonic stem cell-derived motor neurons are sensitive to the toxic effect of glial cells carrying an ALS-causing mutation.

Authors:  Francesco Paolo Di Giorgio; Gabriella L Boulting; Samuel Bobrowicz; Kevin C Eggan
Journal:  Cell Stem Cell       Date:  2008-12-04       Impact factor: 24.633

Review 7.  Cell therapy and stem cells in animal models of motor neuron disorders.

Authors:  Eva Hedlund; Michael P Hefferan; Martin Marsala; Ole Isacson
Journal:  Eur J Neurosci       Date:  2007-10       Impact factor: 3.386

8.  Live imaging of amyotrophic lateral sclerosis pathogenesis: disease onset is characterized by marked induction of GFAP in Schwann cells.

Authors:  A Florence Keller; Mathieu Gravel; Jasna Kriz
Journal:  Glia       Date:  2009-08-01       Impact factor: 7.452

Review 9.  Combining growth factor and stem cell therapy for amyotrophic lateral sclerosis.

Authors:  Masatoshi Suzuki; Clive N Svendsen
Journal:  Trends Neurosci       Date:  2008-03-10       Impact factor: 13.837

10.  Focal transplantation-based astrocyte replacement is neuroprotective in a model of motor neuron disease.

Authors:  Angelo C Lepore; Britta Rauck; Christine Dejea; Andrea C Pardo; Mahendra S Rao; Jeffrey D Rothstein; Nicholas J Maragakis
Journal:  Nat Neurosci       Date:  2008-10-19       Impact factor: 24.884

View more
  6 in total

1.  Gonadectomy and dehydroepiandrosterone (DHEA) do not modulate disease progression in the G93A mutant SOD1 rat model of amyotrophic lateral sclerosis.

Authors:  Antonio Hayes-Punzo; Patrick Mulcrone; Michael Meyer; Jacalyn McHugh; Clive N Svendsen; Masatoshi Suzuki
Journal:  Amyotroph Lateral Scler       Date:  2012-03-13

2.  Cell viability in three ex vivo rat models of spinal cord injury.

Authors:  Azim Patar; Peter Dockery; Linda Howard; Siobhan S McMahon
Journal:  J Anat       Date:  2018-11-11       Impact factor: 2.610

3.  The human G93A-SOD1 mutation in a pre-symptomatic rat model of amyotrophic lateral sclerosis increases the vulnerability to a mild spinal cord compression.

Authors:  Natasa Jokic; Ping K Yip; Adina Michael-Titus; John V Priestley; Andrea Malaspina
Journal:  BMC Genomics       Date:  2010-11-15       Impact factor: 3.969

Review 4.  Spinal cord trauma and the molecular point of no return.

Authors:  Ping K Yip; Andrea Malaspina
Journal:  Mol Neurodegener       Date:  2012-02-08       Impact factor: 14.195

5.  Acute Traumatic Brain Injury Does Not Exacerbate Amyotrophic Lateral Sclerosis in the SOD1 (G93A) Rat Model

Authors:  Gretchen M Thomsen; Jean-Philippe Vit; Alexander Lamb; Genevieve Gowing; Oksana Shelest; Mor Alkaslasi; Eric J Ley; Clive N Svendsen
Journal:  eNeuro       Date:  2015-07-03

6.  Type I Vs. Type II Cytokine Levels as a Function of SOD1 G93A Mouse Amyotrophic Lateral Sclerosis Disease Progression.

Authors:  Amilia Jeyachandran; Benjamin Mertens; Eric A McKissick; Cassie S Mitchell
Journal:  Front Cell Neurosci       Date:  2015-12-01       Impact factor: 5.505

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.